AIC090019

AIC090019 is an investigational small molecule oral antiviral developed by AiCuris for the treatment of chronic hepatitis B virus (HBV) infection. It functions as a non-nucleoside inhibitor of HBV replication, specifically acting as a capsid assembly modulator (CAM) or core protein inhibitor. The compound belongs to the heteroaryldihydropyrimidine (HAP) class, a scaffold originally identified by Bayer, from which AiCuris was spun off. AIC090019 was evaluated in early-phase clinical trials, including a mass balance and metabolite profiling study in the Netherlands, to characterize its pharmacokinetics and metabolism. Development appears to have been discontinued in favor of other candidates or due to strategic shifts in the company's HBV portfolio.